The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

As biotechs faced investors at the J.P. Morgan Healthcare Conference this week, they emphasized agreement with the FDA on ...

Digital patient profiles and real-world data enhance oncology trial design, patient recruitment, and reduce trial failure risks. Phesi's platform aligns trial designs with real-world data, minimizing ...

In a time when COAs are more nuanced, critical and complex than ever, researchers can turn to best practices to move forward ...

Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...

In this GEN webinar, experts from Perceptive Imaging and Flywheel explore how imaging data access issues slow decision-making and increase risks for both biopharma and CROs.

Adaptive clinical trial design represents a modern approach to evaluating healthcare interventions that allows pre‐specified modifications based on accumulating data. This flexible methodology ...

Written agreement from FDA for single-arm, open-label, baseline-controlled registrational trial evaluating composite primary endpoint of improvement in CGI-I and gain of developmental milestone/skill ...